PRL3-zumab for Solid Tumors

Phase 2

Waitlist Available

Research Sponsored by Intra-IMMUSG Pte Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day.

Awards & highlights

No Placebo-Only Group

Summary

This trial tests PRL3-zumab, a medicine given alone through an IV, in patients with tumors that can't be removed by surgery or have spread. The treatment involves regular infusions to help manage the cancer.

Who is the study for?

This trial is for patients with solid tumors that can't be surgically removed or have spread, who've had at least one but no more than three treatments for metastatic disease. They should be relatively active (ECOG score ≤2), expect to live more than six months, and not currently on immunosuppressants or have had recent cancer treatment.

What is being tested?

The study tests PRL3-zumab as a single therapy in people with advanced solid tumors. It's an open-label Phase 2 trial, meaning both researchers and participants know what treatment is being given, and it involves just one dose level of the drug.

What are the potential side effects?

While specific side effects are not listed here, monoclonal antibodies like PRL3-zumab could potentially cause allergic reactions, fatigue, nausea, diarrhea, blood count changes and increase infection risk.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day.

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day. for reporting.